GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Phase of Trial: Phase II/III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs COR-388 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms GAIN
- Sponsors Cortexyme
- 12 Nov 2019 According to an Cortexyme media release, top-line results from the trial expected in the fourth quarter of 2021. The company is evaluating the feasibility of conducting an interim analysis.
- 01 Nov 2019 According to a Cortexyme media release, data from this trial will be presented at the Clinical Trials on Alzheimer Disease (CTAD) 2019 on December 4-7, 2019 in San Diego.
- 26 Sep 2019 According to an Cortexyme media release, the company announced the start of screening of patients in Europe.